ADIPOQ and inherited lipid metabolism disorder: Consistently, pegbelfermin considerably reduced the hepatic fat fraction, the markers of hepatic injury, and the biomarkers of fibrosis, and ameliorated dyslipidaemia and increased adiponectin levels, without significantly changing body weight, in a phase IIa clinical trial in NASH patients [98].